EWEmily L. Williams

Emily L. Williams

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emily L. Williams has a total of 150 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Systemic immunosuppression depletes peripheral blood regulatory B cells in patients with immune thrombocytopenia

    by Madeleine L. Stimpson, Julia Wolf, Bruno Charbit, Emily L. Williams, Philippa J. P. Lait, Lauren P. Schewitz‐Bowers, Richard W. J. Lee, Charlotte A. Bradbury

    Regulatory B (Breg) cells are potentially implicated in the pathogenesis of immune thrombocytopenia (ITP). We analysed a prospective cohort of newly diagnosed steroid naive ITP patients enrolled in the multicentre FLIGHT trial and found that the numbers of Bregs in their peripheral blood were similar to healthy controls. In contrast, Breg numbers were significantly reduced in ITP patients treated with systemic immunosuppression (glucocorticoids or mycophenolate mofetil). We also demonstrate that glucocorticoid treatment impairs Breg interleukin-10 production via an indirect T-cell-mediated mechanism.


  • Open Access

    CD4+ T cells from patients with glucocorticoid‐refractory immune thrombocytopenia have altered cytokine expression

    by Madeleine L. Stimpson, Julia S. Wolf, Emily L. Williams, Philippa J. P. Lait, Lauren P. Schewitz‐Bowers, Rosemary Greenwood, Julie Pell, Ian Thomas, Richard W. J. Lee, Charlotte A. Bradbury


  • Open Access

    Glucocorticoid treatment in patients with newly diagnosed immune thrombocytopenia switches CD14++CD16+ intermediate monocytes from a pro‐inflammatory to an anti‐inflammatory phenotype

    by Emily L. Williams, Madeleine L. Stimpson, Philippa J. P. Lait, Lauren P. Schewitz‐Bowers, Lauren V. Jones, Ashwin D. Dhanda, Richard W. J. Lee, Charlotte A. Bradbury

    Summary: Immune thrombocytopenia (ITP) is thought to result from an aberrant adaptive autoimmune response, involving autoantibodies, B and T lymphocytes, directed at platelets and megakaryocytes. Previous reports have demonstrated skewed CD4+ T‐helper subset distribution and enhanced production of pro‐inflammatory cytokines such as interleukin 17A and interferon gamma. The role of monocytes (MCs) in ITP is less widely described, but innate immune cells have a role in shaping CD4+ T‐cell phenotypes. Glucocorticoids (GCs) are commonly used for first‐line ITP treatment and modulate a broad range of immune cells including T cells and MCs. Using multiparameter flow cytometry analysis, we demonstrate the expansion of intermediate MCs (CD14++CD16+) in untreated patients with newly diagnosed ITP, with these cells displaying a pro‐inflammatory phenotype, characterised by enhanced expression of CD64 and CD80. After 2 weeks of prednisolone treatment (1 mg/kg daily), the proportion of intermediate MCs reduced, with enhanced expression of the anti‐inflammatory markers CD206 and CD163. Healthy control MCs were distinctly different than MCs from patients with ITP before and after GC treatment. Furthermore, the GC‐induced phenotype was not observed in patients with chronic ITP receiving thrombopoietin receptor agonists. These data suggest a role of MCs in ITP pathogenesis and clinical response to GC therapy.


  • IL‐10 and IL‐17 expression by CD4+ T cells is altered in corticosteroid refractory immune thrombocytopenia (ITP)

    by Madeleine L. Stimpson, Philippa J.P. Lait, Lauren P. Schewitz‐Bowers, Emily L. Williams, Kimberley F. Thirlwall, Richard W.J. Lee, Charlotte A. Bradbury


  • Open Access

    Intravenous indocyanine green dye is insufficient for robust immune cell labelling in the human retina

    by Oliver H. Bell, Ester Carreño, Emily L. Williams, Jiahui Wu, David A. Copland, Monalisa Bora, Lina Kobayter, Marcus Fruttiger, Dawn A. Sim, Richard W. J. Lee, et al.

    It is not currently possible to reliably visualise and track immune cells in the human central nervous system or eye. Previous work demonstrated that indocyanine green (ICG) dye could label immune cells and be imaged after a delay during disease in the mouse retina. We report a pilot study investigating if ICG can similarly label immune cells within the human retina. Twelve adult participants receiving ICG angiography as part of routine standard of care were recruited. Baseline retinal images were obtained prior to ICG administration then repeated over a period ranging from 2 hours to 9 days. Matched peripheral blood samples were obtained to examine systemic immune cell labelling and activation from ICG by flow cytometry with human macrophage cultures as positive controls. Differences between the delayed near infrared ICG imaging and 488 nm autofluorescence was observed across pathologies, likely arising from the retinal pigment epithelium (RPE). Only one subject demonstrated ICG signal on peripheral blood myeloid cells and only three distinct cell-sized signals appeared over time within the retina of three participants. No significant increase in immune cell activation markers were detected after ICG administration. ICG accumulated in the endosomes of macrophage cultures and was detectable above a minimum concentration, suggesting cell labelling is possible. ICG can label RPE and may be used as an additional biomarker for RPE health across a range of retinal disorders. Standard clinical doses of intravenous ICG do not lead to robust immune cell labelling in human blood or retina and further optimisation in dose and route are required.


  • Intermediate Monocytes in Acute Alcoholic Hepatitis Are Functionally Activated and Induce IL-17 Expression in CD4+ T Cells

    by Ashwin D. Dhanda, Emily L. Williams, Euan Yates, Philippa J. P. Lait, Lauren P. Schewitz-Bowers, Doha Hegazy, Matthew E. Cramp, Peter L. Collins, Richard W. J. Lee

    In humans, the three main circulating monocyte subsets are defined by their relative cell surface expression of CD14 and CD16. They are all challenging to study because their characteristics are strongly context specific, and this has led to a range of conflicting reports about their function, which is especially so for CD14++CD16+ (intermediate) monocytes. Ex vivo cultures are also often confounded by the concomitant use of immunosuppressive drugs. We therefore sought to characterize the phenotype and function of intermediate monocytes in the setting of acute inflammation prior to treatment in a cohort of 41 patients with acute alcoholic hepatitis (AH). Circulating intermediate monocytes were enriched in patients with AH and had an activated phenotype with enhanced expression of CCR2 and CD206 compared with healthy controls. Proinflammatory cytokine expression, including IL-1β and IL-23, was also higher than in healthy controls, but both classical (CD14++CD16−) and intermediate monocytes in AH were refractory to TLR stimulation. Compared with healthy controls, both AH monocyte subsets had greater phagocytic capacity, enhanced ability to drive memory T cell proliferation in coculture, and skewed CD4+ T cells to express an increased ratio of IL-17/IFN-γ. Furthermore, liver tissue from AH patients demonstrated an enrichment of monocytes including the intermediate subset compared with controls. These data demonstrate that intermediate monocytes are expanded, functionally activated, induce CD4+ T cell IL-17 expression, and are enriched in the liver of patients with AH. Key Points Circulating intermediate monocytes are enriched in AH patients. AH intermediate monocytes are functionally activated. AH intermediate monocytes induce CD4+ T cell IL-17 and are enriched in the liver.


  • Open Access

    Intravenous indocyanine green dye is insufficient for robust immune cell labelling in the human retina

    by Oliver Hugh Bell, Ester Carreño, Emily L. Williams, Jiahui Wu, David A. Copland, Monalisa Bora, Lina Kobayter, Marcus Fruttiger, Dawn A. Sim, Richard W.J. Lee, et al.

    It is not currently possible to reliably visualise and track immune cells in the human central nervous system or eye. Previous work demonstrated that indocyanine green (ICG) dye could label immune cells and be imaged after a delay during disease in the mouse retina. We report a pilot study investigating if ICG can similarly label immune cells within the human retina. Twelve adult participants receiving ICG angiography as part of routine standard of care were recruited. Baseline retinal images were obtained prior to ICG administration then repeated over a period ranging from 2 hours to 9 days. Matched peripheral blood samples, in addition to human and mouse macrophage cultures as controls, were analysed by flow cytometry. Differences between the delayed near infrared ICG imaging and 488 nm autofluorescence was observed across pathologies, likely arising from the retinal pigment epithelium (RPE). Only one subject demonstrated ICG signal on peripheral blood myeloid cells and only three distinct cell-sized signals appeared over time within the retina of three participants. No significant increase in immune cell activation markers were detected after ICG administration. ICG accumulated in the endosomes of macrophage cultures and was detectable above a minimum concentration, suggesting cell labelling is possible. ICG can label RPE and may be used as an additional biomarker for cell health across a range of retinal disorders. Standard clinical doses of intravenous ICG do not lead to robust immune cell labelling in human blood or retina and further optimisation in dose and route are required.

  • Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function

    by Sarah L. Buchan, Lang Dou, Marcus Remer, Steven G. Booth, Stuart N. Dunn, Chester Lai, Monika Semmrich, Ingrid Teige, Linda Mårtensson, Christine A. Penfold, et al.


  • Open Access

    Development and validation of a novel bioassay to determine glucocorticoid sensitivity

    by Emily L. Williams, Madeleine L. Stimpson, Peter L. Collins, Doyo G. Enki, Ashish Sinha, Richard W. Lee, Ashwin D. Dhanda

    Glucocorticoids (GCs) remain the first line treatment for almost all non-infectious inflammatory diseases, ranging from acute asthma to rheumatoid arthritis. However, across all conditions, patients have a variable response to GCs with approximately 30% being non-responders. This group of GC resistant patients is typically exposed to high-dose GCs and their side-effects before more appropriate immunotherapy is instituted. Hence, there is a pressing clinical need for a predictive biomarker of GC responsiveness. The availability of such a tool would also enable patient stratification for the conduct of smart clinical trials in GC resistance. Lymphocyte GC sensitivity has been shown to be closely associated with clinical GC sensitivity in a number of inflammatory diseases. However, the method for determining in vitro GC response is not standardized and requires the use of specialist equipment, including a radioisotope to quantify cellular proliferation, making it challenging to translate into clinical practice. Here we describe the optimization and validation of a novel non-radioactive in vitro bioassay based on measuring cellular proliferation by incorporation of bromodeoxyuridine (BrdU), termed the BrdU incorporation in lymphocyte steroid sensitivity assay (BLISS). In comparison to the current gold standard lymphocyte GC sensitivity assay in 101 healthy control samples, BLISS has an area under receiver operating characteristic of 0.82 and a sensitivity of 83% for correctly identifying GC resistant subjects. The performance of the novel BLISS bioassay makes it a strong candidate biomarker for clinical application. It now requires validation in a prospective patient cohort.